Peptides DB
Research-centric peptide and protocol reference hub

Research library

Every indexed study on every peptide in the database, with a machine summary and the numbers that matter pulled out. Filter on the left; the register updates as you go.

2255studies indexed1010with human data129registered trials1946carry a numeric findingLibrarian added 23 studies today
Showing 28 studiesSortNewest indexed
C
grade
Novel GnRH analogue decorated paclitaxel and CQDs co-loaded theranostic zein nanoparticles for treatment of breast cancer: Formulation optimization, in vitro and in vivo evaluation.
Leuprorelin · International journal of biological macromolecules · 2026 · Animal study · Preclinical
Leuprorelin-decorated nanoparticles show promise in improving breast cancer treatment efficacy and safety in preclinical models, but human trials are needed to confirm these findings.
Particle size of 154.23 ± 7.51 nm.
B
grade
A follow-up study of a randomized controlled study evaluating safety and efficacy of leuprorelin acetate every-3-month depot for 2 versus 3 or more years with tamoxifen for 5 years as adjuvant treatment in premenopausal patients with endocrine-responsive breast cancer.
Leuprorelin · Breast cancer (Tokyo, Japan) · 2021 · Observational
Leuprorelin treatment for ≥3 years does not show a significant benefit over 2 years in overall disease-free survival for premenopausal breast cancer patients, but may offer advantages for higher-risk individuals.
HR 0.944, 95% CI 0.486-1.8392 for DFS between ≥3 years and 2 years.
B
grade
Effects of leuprorelin acetate microspheres on sex hormones, secondary sexual characteristics, and predicted adult height in early and fast puberty girls: a real-world, single-arm, retrospective cohort study.
Leuprorelin · Translational pediatrics · 2023 · Observational · n=198
Leuprorelin acetate microspheres may suppress sex hormones and increase predicted adult height in girls with early and fast puberty, but the clinical relevance of these findings needs further investigation.
Median LH decreased from 2.7 (2.23-3.51) mIU/mL at T0 to 0.66 (0.48-1.22) mIU/mL at T4, P<0.001.
A
grade
24-week home-based walking program in the early adjuvant setting in breast cancer patients who receive aromatase inhibitor endocrine therapy: lessons learned from the SAKK 95/17 WISE prospective, randomized, multicenter trial.
Leuprorelin · Breast (Edinburgh, Scotland) · 2026 · RCT · Phase 4 · n=320
A structured walking program increased daily step counts in breast cancer patients on aromatase inhibitors, but did not significantly reduce pain or AIA symptoms.
Median daily number of steps was higher in arm A (8542 vs. 7742; p=0.015).
B
grade
Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study.
Leuprorelin · Breast (Edinburgh, Scotland) · 2026 · Observational · n=597
In patients with hormone receptor-positive/HER2-negative metastatic breast cancer, HER2-low status is linked to shorter progression-free survival when treated with CDK4/6 inhibitors.
Median rwPFS was 28.1 months at a median follow-up of 41 months.
Showing 25 of 28